ImageneBio (IMA) Stock Price, News & Analysis

ImageneBio logo
$3.12 -0.08 (-2.34%)
As of 10:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About ImageneBio Stock (NASDAQ:IMA)

Advanced

Key Stats

Today's Range
$3.00
▼
$3.20
50-Day Range
$3.20
▼
$5.08
52-Week Range
$3.00
▼
$7.89
Volume
14,791 shs
Average Volume
113,032 shs
Market Capitalization
$35.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00
Consensus Rating
Hold

Company Overview

ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Its research and development pipeline includes investigational medicines at various stages of clinical development; the company does not yet have marketed products.

Key programs include IMG-007, an investigational antibody targeting OX40 being studied for atopic dermatitis and other inflammatory conditions, and IMG-004, an oral investigational BTK inhibitor for immune-mediated diseases. These candidates remain in development and have not been approved for commercial use.

ImageneBio was formed through the combination of I-Mab and Inmagene Biopharmaceuticals, bringing together drug-development programs and expertise in biotechnology. Its work is centered on advancing clinical research, with potential uses for its therapies to be assessed through ongoing studies.

AI Generated. May Contain Errors.

ImageneBio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

IMA MarketRank™: 
2.975905218315 of 5 stars

ImageneBio scored higher than 60% of companies evaluated by MarketBeat, and ranked 434th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ImageneBio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 2 sell ratings.

  • Upside Potential

    ImageneBio has a consensus price target of $28.00, representing about 775.0% upside from its current price of $3.20.

  • Amount of Analyst Coverage

    ImageneBio has only been the subject of 2 research reports in the past 90 days.

  • Read more about ImageneBio's stock forecast and price target.
  • Earnings Growth

    Earnings for ImageneBio are expected to grow in the coming year, from ($3.47) to ($3.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImageneBio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImageneBio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ImageneBio has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.41% of the float of ImageneBio has been sold short.
  • Short Interest Ratio / Days to Cover

    ImageneBio has a short interest ratio ("days to cover") of 3.96, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImageneBio has recently decreased by 25.09%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ImageneBio does not currently pay a dividend.

  • Dividend Growth

    ImageneBio does not have a long track record of dividend growth.

  • News Sentiment

    ImageneBio has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for ImageneBio this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for IMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ImageneBio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.22% of the stock of ImageneBio is held by insiders.

  • Percentage Held by Institutions

    75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ImageneBio's insider trading history.
Receive IMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImageneBio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMA Stock News Headlines

ImageneBio Reports Third Quarter 2026 Financial Results
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
ImageneBio Corporate Event Calendar | NASDAQ:IMA
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
See More Headlines

IMA Stock Analysis - Frequently Asked Questions

ImageneBio's stock was trading at $6.90 on January 1st, 2026. Since then, IMA stock has decreased by 53.6% and is now trading at $3.20.

ImageneBio, Inc. (NASDAQ:IMA) announced its quarterly earnings data on Monday, November, 9th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.08.

ImageneBio's stock reverse split before market open on Monday, July 28th 2025.The 1-12 reverse split was announced on Friday, July 25th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Top institutional investors of ImageneBio include Blue Owl Capital Holdings LP (10.00%) and Goldman Sachs Group Inc. (0.10%). Insiders that own company stock include Otello Stampacchia, David P Bonita and Joseph P Slattery.
View institutional ownership trends
.

Shares of IMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImageneBio investors own include NVIDIA (NVDA), Rain Enhancement Technologies Holdco (RAIN), Alphabet (GOOG), Immunic (IMUX), Lucid Group (LCID), Micron Technology (MU) and Nebius Group (NBIS).

Company Calendar

Last Earnings
11/09/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMA
Previous Symbol
NASDAQ:IMA
CIK
1835579
Fax
N/A
Employees
18
Year Founded
2016

Price Target and Rating

High Price Target
$28.00
Low Price Target
$28.00
Potential Upside/Downside
+795.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.35 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-32.90%
Return on Assets
-29.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.17
Quick Ratio
21.47

Sales & Book Value

Annual Sales
$800 thousand
Price / Sales
44.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.29 per share
Price / Book
0.28

Miscellaneous

Outstanding Shares
11,350,000
Free Float
12,179,000
Market Cap
$35.48 million
Optionable
Not Optionable
Beta
0.83

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:IMA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners